Talaris Therapeutics GAAP EPS of -$0.90

* Talaris Therapeutics press release [https://seekingalpha.com/pr/20199100-tourmaline-bio-reports-second-quarter-2025-financial-results-and-recent-business-highlights] (NASDAQ:TRML [https://seekingalpha.com/symbol/TRML]): Q2 GAAP EPS of -$0.90.
* Cash, cash equivalents, and investments were $256.4 million as of June 30, 2025, as compared to $294.9 million as of December 31, 2024.
*  

MORE ON TALARIS THERAPEUTICS

* Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition [https://seekingalpha.com/article/4788620-tourmaline-bio-tranquility-study-data-lends-credibility-for-il-6-inhibition]
* Tourmaline Bio posts mid-stage data for anti-inflammatory agent [https://seekingalpha.com/news/4450417-tourmaline-bio-stock-slips-trial-data]
* Seeking Alpha’s Quant Rating on Talaris Therapeutics [https://seekingalpha.com/symbol/TRML/ratings/quant-ratings]
* Historical earnings data for Talaris Therapeutics [https://seekingalpha.com/symbol/TRML/earnings]
* Financial information for Talaris Therapeutics [https://seekingalpha.com/symbol/TRML/income-statement]